Adherex Technologies Inc. (TSX:AHX) (AMEX:ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced its global development plans for the chemoenhancer eniluracil, which the Company in-licensed from GlaxoSmithKline (GSK) in July 2005. The Company expects to have eniluracil into Phase III trials by mid 2007.
